Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 vs Physician's Choice in Advanced Biliary Tract Cancer
NCT07582315Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in biliary tract cancer (BTC), sponsored by Biokin Pharmaceutical. Started Jun 2026; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07582315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582315.